Your session is about to expire
← Back to Search
Corticosteroid
Corticosteroids for Esophagogastric Junction Obstruction
Phase < 1
Recruiting
Led By Chanakyaram Reddy, MD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adult patients age 18 years or older with EGJOO manometric diagnosis based on CC v4.0 criteria
Primary symptom of dysphagia and/or non-cardiac chest pain
Must not have
Contraindication to the use of oral corticosteroids
History of prior foregut surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed upon being on study intervention medication for 14 days
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to investigate if corticosteroid medications can improve the function of the esophageal muscles in patients with a disorder called EGJ outflow obstruction (EGJOO), which causes swallowing
Who is the study for?
This trial is for individuals with EGJOO, a condition where the esophagus muscles don't work well together, causing swallowing difficulties and chest pain. Participants must meet certain criteria not specified here.
What is being tested?
The study tests if corticosteroids can improve esophageal muscle function in EGJOO patients. It involves steroid treatment, measuring muscle movement with esophageal manometry, and completing surveys about symptoms.
What are the potential side effects?
Corticosteroid use may lead to side effects such as increased infection risk, changes in blood sugar levels, mood swings, weight gain, insomnia, and possibly weakening of bones.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 or older and have been diagnosed with EGJ outflow obstruction.
Select...
I have difficulty swallowing and/or chest pain not related to heart issues.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I cannot take oral corticosteroids due to health reasons.
Select...
I have had surgery on my upper digestive tract.
Select...
I am currently on medication that affects my immune system.
Select...
I have Eosinophilic Esophagitis without control and haven't tried standard treatments.
Select...
I have a hiatal hernia larger than 2 centimeters.
Select...
I have a mass in my esophagus.
Select...
I have a blockage in my esophagus found during an endoscopy.
Select...
I have moderate to severe acid reflux disease.
Select...
I have had a blockage at the junction of my stomach and esophagus.
Select...
I have been diagnosed with diabetes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ assessed upon being on study intervention medication for 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed upon being on study intervention medication for 14 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Response in esophageal motility to study intervention
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Steroid TreatmentExperimental Treatment3 Interventions
All participants are in the treatment arm. Patients with Esophagogastric Junction Outflow Obstruction (EGJOO) will undergo steroid treatment for 14 days. On the last day of the 14 day treatment, patient will undergo esophageal manometry testing to assess for treatment response. They will also be asked to complete follow-up Eckardt and BEDQ surveys.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Esophageal Manometry
2013
N/A
~40
Steroid treatment
2012
Completed Phase 4
~40
Find a Location
Who is running the clinical trial?
Baylor Research InstituteLead Sponsor
206 Previous Clinical Trials
203,415 Total Patients Enrolled
Chanakyaram Reddy, MDPrincipal InvestigatorBaylor Health Care System